公开(公告)号：US20210113630A1

公开(公告)日：2021-04-22

申请号：US16625429

申请日：2018-06-21

Applicant: ABBOTT LABORATORIES

Inventor： Alejandro Perez BARRANCO ,  Maria Gonzalez RAMIREZ ,  Rachael BUCK ,  Enrique Hernandez VAZQUEZ

IPC: A61K35/747 ,  A61K31/702 ,  A61K31/355 ,  A61K31/047 ,  A61K35/745 ,  A61K35/20 ,  A61K9/107 ,  A61K47/46 ,  A61K47/44 ,  A61K47/26 ,  A61K47/24 ,  A61K47/02 ,  A61K47/22 ,  A61K47/42 ,  A61K47/36 ,  A61K47/12 ,  A61K31/07 ,  A61K31/122 ,  A61K31/593 ,  A61K31/714 ,  A61K31/015 ,  A61K31/519 ,  A61K31/4188 ,  A61K31/525 ,  A61K31/4415 ,  A61K47/14 ,  A61K31/405 ,  A61K31/205 ,  A61K31/14 ,  A61K31/145 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/7072 ,  A61K33/06 ,  A61K33/30 ,  A61K33/26 ,  A61P1/14 ,  A23L33/00 ,  A23L33/125 ,  A23L33/15 ,  A23L33/135

Abstract: Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.